# Natera, Inc. – Consensus ‘strong_buy’ rating and 6.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/natera-inc-consensus-strong-buy-rating-and-6-8-upside-potential/4121185420
- Published: 2025-01-31T13:30:48+00:00
- Author: Charlotte Edwards

**Natera, Inc.** with ticker code (NTRA) now have 19 market analysts covering the
stock. The analyst consensus now points to a rating of ‘strong_buy’. The range between
the high target price and low target price is between $210.00 and $37.00 with the
average target price sitting at $179.67. Given that the stocks previous close was
at $168.22 this would imply there is now a potential upside of 6.8%. The 50 day 
MA is $165.69 while the 200 day moving average is $126.26. The market capitalization
for the company is 23.27B. The current share price for the company is: $176.27 USD

 The potential market cap would be $24,854,738,195 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $12.59 and
a -9.96% return on assets.

Natera, Inc. is a diagnostics company that is focused on the development and commercialization
of molecular testing services, applying its technology in the fields of women’s 
health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology
combines its molecular assays, which reliably measure many informative regions across
the genome from samples as small as a single cell. The Company’s product offerings
include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening(
HCS), Spectrum Preimplantation Genetics, Anora Miscarriage Test (Anora) and Prospera.
The Company also offers Constellation, a cloud-based software platform that enables
laboratory customers to gain access through the cloud to the Company’s algorithms
and bioinformatics in order to validate and launch tests based on the Company’s 
technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as
in twin pregnancies, typically with a blood draw from the mother.

Share on:
